Register for the Incyte Mentor Program and connect with another patient taking Jakafi.
Register for the Incyte Mentor
Program and connect with another
patient taking Jakafi.
The spleen is a small organ located near the stomach under your left rib cage. Among its many important functions, the spleen helps your body with:
Healthy red blood cells (A) are able to pass back into circulation through small holes or slits in veins (B) in the spleen, while old or damaged cells (C) cannot and are broken down.
Images, including enlarged spleen above, are shown for illustrative purposes.
Watch Myelofibrosis, Spleen Size & You
Take a closer look at the various functions of the spleen and learn more about why spleen size is an important health focus for people with MF.
Typically, the spleen is about the size of your fist. However, in people with myelofibrosis (MF), it may become enlarged.
In people with MF, scar tissue builds up within the bone marrow, preventing it from making enough normal blood cells. Red blood cell and platelet counts typically decrease over time, while white blood cell counts may increase or decrease. The spleen partially takes over blood cell production, and this may make the spleen get bigger—a condition called splenomegaly (splee-nuh-MEG-uh-lee). This is a common finding in people with MF.
An enlarged spleen can be a sign that your spleen is working harder than normal. However, in some patients with MF, it may also be a sign of disease progression, which means that your MF is changing or getting worse.
In one clinical study, about 90% (681 of 768) of people living with MF had an enlarged spleen at diagnosis.
Because the spleen is located in your abdominal area, an enlarged spleen may press on the stomach, making it difficult for the stomach to expand normally when eating. Symptoms of an enlarged spleen may include:
It’s important to remember to talk to your Healthcare Professional about all of your symptoms, even if you're not sure they’re related to your MF.
It’s important to work with your Healthcare Professional to establish your “baseline” spleen size at diagnosis—or as early on as possible. Your Healthcare Professional can check your spleen size by gently feeling or “palpating” your left upper abdominal area. Because it can sometimes be difficult to accurately measure spleen size through physical examination alone, your Healthcare Professional may order an imaging test. These tests may include:
Computed tomography (CT),
also called a CT scan
Magnetic resonance imaging (MRI)
Early identification of an enlarged spleen is important and may help your Healthcare Professional to reassess your care management approach sooner if your MF is progressing. Remember, it’s important to work with your care team to regularly keep track of any changes in your spleen size or symptoms.
Recognizing the signs and symptoms of spleen enlargement can help you take a more active role in your ongoing MF care. Learn what questions you should be asking yourself before your next MF care visit.
Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
Jakafi is used to treat adults with certain types of myelofibrosis.
Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.
Jakafi is also used to treat adults and children 12 years of age and older with chronic GVHD who have taken one or two types of treatments and they did not work well enough.
Jakafi can cause serious side effects, including:
Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.
Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.
Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.
Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.
Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech.
Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing.
Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.
The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.
These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.
Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.
Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.
Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
You may also report side effects to Incyte Medical Information at 1-855-463-3463.